Literature DB >> 22025707

Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10.

Dorothy K Sojka1, Deborah J Fowell.   

Abstract

CD4(+)CD25(+)Forkhead box P3 (Foxp3)(+) regulatory T cells (Tregs) control immune responses to self and foreign antigens in secondary lymphoid organs and at tissue sites of inflammation. Tregs can modify the function of many immune cells and have been proposed to block early proliferation, differentiation, and effector function. Acute ablation of Tregs has revealed rapid cytokine production immediately after Treg removal, suggesting that Tregs may regulate effector function acutely rather than regulating the programming for immune function. We developed in vitro and in vivo models that enabled the direct test of Treg regulation of T-helper cell type 1 (Th1) differentiation. CD28 signaling is known to abrogate Treg suppression of IL-2 secretion and proliferation, but our studies show that Treg suppression of IFN-γ during Th1 priming proceeds despite enhanced CD28 signaling. Importantly, during Th1 differentiation, Tregs inhibited early IFN-γ transcription without disrupting expression of Th1-specific T-box transcription factor (Tbet) and Th1 programming. Acute shutoff of effector cytokine production by Tregs was selective for IFN-γ but not TNF-α and was independent of TGF-β and Epstein-Barr virus-induced gene 3. In vivo, Tregs potently controlled CD4 IFN-γ and CD4 effector cell expansion in the lymph node (four- to fivefold reduction) but not Th1 programming, independent of IL-10. Tregs additionally reduced CD4 IFN-γ in the inflamed dermis (twofold reduction) dependent on their production of IL-10. We propose a model for Treg inhibition of effector function based on acute cytokine regulation. Interestingly, Tregs used different regulatory mechanisms to regulate IFN-γ (IL-10-dependent or -independent) subject to the target T-cell stage of activation and its tissue location.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025707      PMCID: PMC3215041          DOI: 10.1073/pnas.1110566108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation.

Authors:  Ashutosh Chaudhry; Robert M Samstein; Piper Treuting; Yuqiong Liang; Marina C Pils; Jan-Michael Heinrich; Robert S Jack; F Thomas Wunderlich; Jens C Brüning; Werner Müller; Alexander Y Rudensky
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion.

Authors:  Nadia Sarween; Anna Chodos; Chandra Raykundalia; Mahmood Khan; Abul K Abbas; Lucy S K Walker
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

3.  Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways.

Authors:  Mariano Sanchez-Lockhart; Elides Marin; Beth Graf; Ryo Abe; Yohsuke Harada; Caitlin E Sedwick; Jim Miller
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

4.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.

Authors:  L Ding; P S Linsley; L Y Huang; R N Germain; E M Shevach
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

5.  T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells.

Authors:  Maryam Afkarian; John R Sedy; Jianfei Yang; Nils G Jacobson; Nezih Cereb; Soo Y Yang; Theresa L Murphy; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2002-05-13       Impact factor: 25.606

6.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.

Authors:  T Lindstein; C H June; J A Ledbetter; G Stella; C B Thompson
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

7.  Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10.

Authors:  Chrystelle Asseman; Simon Read; Fiona Powrie
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

9.  An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.

Authors:  C Asseman; S Mauze; M W Leach; R L Coffman; F Powrie
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  40 in total

1.  Epigenetic alterations may regulate temporary reversal of CD4(+) T cell activation caused by trichloroethylene exposure.

Authors:  Kathleen M Gilbert; Ashley R Nelson; Craig A Cooney; Brad Reisfeld; Sarah J Blossom
Journal:  Toxicol Sci       Date:  2012-03-09       Impact factor: 4.849

2.  Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis.

Authors:  Zhi-Ming Dai; Ai-Li He; Wang-Gang Zhang; Jie Liu; Xing-Mei Cao; Yin-Xia Chen; Xiao-Rong Ma; Wan-Hong Zhao; Zhi-Jun Dai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.

Authors:  Susan A Olalekan; Yanxia Cao; Keith M Hamel; Alison Finnegan
Journal:  Eur J Immunol       Date:  2015-02-11       Impact factor: 5.532

Review 4.  Lymphocytes and macrophages in adipose tissue in obesity: markers or makers of subclinical inflammation?

Authors:  Anna Cinkajzlová; Miloš Mráz; Martin Haluzík
Journal:  Protoplasma       Date:  2017-02-01       Impact factor: 3.356

5.  Programming of Distinct Chemokine-Dependent and -Independent Search Strategies for Th1 and Th2 Cells Optimizes Function at Inflamed Sites.

Authors:  Alison Gaylo-Moynihan; Hen Prizant; Milan Popović; Ninoshka R J Fernandes; Christopher S Anderson; Kevin K Chiou; Hannah Bell; Dillon C Schrock; Justin Schumacher; Tara Capece; Brandon L Walling; David J Topham; Jim Miller; Alan V Smrcka; Minsoo Kim; Angela Hughson; Deborah J Fowell
Journal:  Immunity       Date:  2019-08-06       Impact factor: 31.745

6.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

Review 7.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.

Authors:  Prabhakaran Kumar; Shikha Saini; Saad Khan; Swarali Surendra Lele; Bellur S Prabhakar
Journal:  Cell Immunol       Date:  2018-09-29       Impact factor: 4.868

Review 8.  Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.

Authors:  Fadi Saade; Stacey Ann Gorski; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

9.  Engagement of Toll-like receptor 2 enhances interleukin (IL)-17(+) autoreactive T cell responses via p38 mitogen-activated protein kinase signalling in dendritic cells.

Authors:  R Wei; L Dong; Q Xiao; D Sun; X Li; H Nian
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

10.  Orchestration of CD4 T cell epitope preferences after multipeptide immunization.

Authors:  Jacqueline Tung; Andrea J Sant
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.